Heart failure (HF) is frequently associated with diabetes and has limited treatment options, and treating people with HF and preserved ejection fraction (HFpEF) is even more challenging. Previous trials for sodium-glucose co-transporter-2 (SGLT-2) inhibitors have demonstrated significant favorable outcomes for cardiovascular disease, HF hospitalization, and all-cause mortality cases. 1 Therefore, EMPEROR-Preserved trial was conducted to evaluate the effect of empagliflozin in HFpEF patients with and without type 2 diabetes mellitus. 2 In this regard, Boehringer Ingelheim, India, and Docplexus have organized an interactive webinar on 28 th August 2021, 4:00 PM onwards. In this webinar, Dr.
Subodh Verma and Dr. V. K. Chopra will share their insights on the results of the EMPEROR Preserved trial. We invite you to ask questions that the experts will answer at the end of the session.…
